Open AccessComparison of the effects of weekly and biweekly intravenous CERA administration on erythropoiesis: A randomized controlled trial
Author(s) -
Kawai Yuki,
Toya Yoshiyuki,
Wakui Hiromichi,
Fujikawa Tetsuya,
Ueda Eiko,
Azushima Kengo,
Mitsuhashi Hiroshi,
Kawano Tomoyuki,
Kuji Tadashi,
Yamaguchi Satoshi,
Ohnishi Toshimasa,
Tamura Kouichi
Publication year - 2021
Publication title -
the journal of clinical hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 67
eISSN - 1751-7176
pISSN - 1524-6175
DOI - 10.1111/jch.14171
Subject(s) - medicine , interquartile range , anemia , erythropoiesis , erythropoietin , randomized controlled trial , hemoglobin , hemodialysis , clinical endpoint , surgery
Although continuous erythropoietin receptor activators (CERAs) are widely used erythropoiesis‐stimulating agents for correcting renal anemia in patients undergoing hemodialysis (HD), few reports have examined weekly CERA administration. In this randomized controlled trial, we compared the efficacy and changes in the parameters of iron metabolism and erythropoiesis between weekly and biweekly CERA administration. In total, 120 patients undergoing maintenance HD were randomized to the weekly or biweekly group. The primary end point was the total CERA dose needed to maintain the target hemoglobin (Hb) levels during a 12‐week evaluation period. There was no significant difference in the total dose between the weekly and biweekly groups (median 175.0 [interquartile range (IQR) 93.8–337.5] µg/12 weeks vs. 300.0 [IQR 125.0–375.0] µg/12 weeks, P = .18). The mean Hb levels during the evaluation period were 10.9 ± 0.8 g/dL in the weekly group and 10.7 ± 0.8 g/dL in the biweekly group ( P = .25). Weekly CERA administration was well tolerated. Weekly CERA administration similarly managed anemia as biweekly administration in patients undergoing HD.